Binge Eating Disorder: A 5-Year Retrospective Study on Experimental Drugs

References

• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth ed. Washington DC: American Psychiatric Association; 2013.
   Google Scholar
• Kornstein SG, Kunovac JL, Herman BK, et al. Recognizing binge-eating disorder in the clinical setting: a review of the literature. Prim Care Companion CNS Disord. 2016;18(3). doi:10.4088/PCC.15r01905
   Google Scholar
• Guerdjikova AI, McElroy SL, Winstanley EL, et al. Duloxetine in the treatment of binge eating disorder with depressive disorders: a placebo-controlled trial. Int J Eat Disord. 2012;45(2):281–289. doi:10.1002/eat.20946
   PubMed Web of Science ®Google Scholar
• Javaras KN, Pope HG, Lalonde JK, et al. Co-occurrence of binge-eating disorder with psychiatric and medical disorders. J Clin Psychiatry. 2008;69(2):266–273. doi:10.4088/JCP.v69n0213
   PubMed Web of Science ®Google Scholar
• Friborg O, Martinussen M, Kaiser S, et al. Personality disorders in eating disorder not otherwise specified and binge eating disorder: a meta-analysis of comorbidity studies. J Nerv Ment Dis. 2014;202(2):119–125. doi:10.1097/NMD.0000000000000080
   Web of Science ®Google Scholar
• Kessler RC, Berglund PA, Chiu WT, et al. The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys. Biol Psychiatry. 2013;73:904–914. doi:10.1016/j.biopsych.2012.11.020
   PubMed Web of Science ®Google Scholar
• Dingemans AE, van Furth EF. Binge eating disorder psychopathology in normal weight and obese individuals. Int J Eat Disord. 2012;45(1):135–138. doi:10.1002/eat.20905
   Web of Science ®Google Scholar
• Linna MS, Raevuori A, Haukka J, et al. Reproductive health outcomes in eating disorders. Int J Eat Disord. 2013;46(8):826–833. doi:10.1002/eat.22179
   PubMed Web of Science ®Google Scholar
• Raevuori A, Suokas J, Haukka J, et al. Highly increased risk of type 2 diabetes in patients with binge eating disorder and bulimia nervosa. Int J Eat Disord. 2015;48(6):555–562. doi:10.1002/eat.22334
   PubMed Web of Science ®Google Scholar
• Masheb RM, Grilo CM. Quality of life in patients with binge eating disorder. Eat Weight Disord. 2004;9(3):194–199. doi:10.1007/BF03325066
   Google Scholar
• Vancampfort D, Probst M, Adriaens A, et al. Clinical correlates of global functioning in obese treatment seeking persons with binge eating disorder. Psychiatr Danub. 2014;26(3):256–260.
   Web of Science ®Google Scholar
• de Zwaan M, Herpertz S, Zipfel S, et al. INTERBED: internet-based guided self-help for overweight and obese patients with full or subsyndromal binge eating disorder. A multicenter randomized controlled trial. Trials. 2012;13(1):220. doi:10.1186/1745-6215-13-220
   Web of Science ®Google Scholar
• Wassenaar E, Friedman J, Mehler PS. Medical complications of binge eating disorder. Psychiatr Clin North Am. 2019;42(2):275–286. doi:10.1016/j.psc.2019.01.010
   PubMed Web of Science ®Google Scholar
• Cossrow N, Pawaskar M, Witt EA, et al. Estimating the prevalence of binge eating disorder in a community sample from the United States: comparing DSM-IV-TR and DSM-5 criteria. J Clin Psychiatry. 2016;77(8):e968–e974. doi:10.4088/JCP.15m10059
   PubMed Web of Science ®Google Scholar
• Yager J, Devlin M, Halmi K, et al. Guideline Watch Practice Guideline for the Treatment of Patients with Eating Disorders. 3. Arlington, VA: American Psychiatric Assoc; 2012:1–18.
   Google Scholar
• National Institute for Health and Care Excellence [NICE]; 2013. Available from: http://www.nice.org.uk. Accessed January 12, 2021.
   Google Scholar
• Brownley KA, Berkman ND, Peat CM, et al. Binge-eating disorder in adults: a systematic review and meta-analysis. Ann Intern Med. 2016;165(6):409–420. doi:10.7326/M15-2455
   PubMed Web of Science ®Google Scholar
• Reas DL, Grilo CM. Review and meta-analysis of pharmacotherapy for binge-eating disorder. Obesity (Silver Spring). 2008;16(9):2024–2038. doi:10.1038/oby.2008.333
   PubMed Web of Science ®Google Scholar
• Kessler RM, Hutson PH, Herman BK, et al. The neurobiological basis of binge-eating disorder. Neurosci Biobehav Rev. 2016;63:223–238. doi:10.1016/j.neubiorev.2016.01.013
   PubMed Web of Science ®Google Scholar
• Kuikka JT, Tammela L, Karhunen L, et al. Reduced serotonin transporter binding in binge eating women. Psychopharmacology (Berl). 2001;155(3):310–314. doi:10.1007/s002130100716
   Web of Science ®Google Scholar
• Gibb A, Deeks ED. Vortioxetine: first global approval. Drugs. 2014;74(1):135–145. doi:10.1007/s40265-013-0161-9
   PubMed Web of Science ®Google Scholar
• McElroy SL, Mori N, Guerdjikova AI, et al. Would glucagon-like peptide-1 receptor agonists have efficacy in binge eating disorder and bulimia nervosa? A review of the current literature. Med Hypotheses. 2018;111:90–93. doi:10.1016/j.mehy.2017.12.029
   PubMed Web of Science ®Google Scholar
• Culbert KM, Racine S, Klump KL. Hormonal factors and disturbances in eating disorders. Curr Psychiatry Rep. 2016;18(7). doi:10.1007/s11920-016-0701-6
   Web of Science ®Google Scholar
• Leslie M, Leppanen J, Paloyelis Y, et al. The influence of oxytocin on eating behaviours and stress in women with bulimia nervosa and binge eating disorder. Mol Cell Endocrinol. 2019;497:110354. doi:10.1016/j.mce.2018.12.014
   Web of Science ®Google Scholar
• Guerdjikova AI, Mori N, Casuto LS, McElroy SL. Novel pharmacologic treatment in acute binge eating disorder - role of lisdexamfetamine. Neuropsychiatr Dis Treat. 2016;12:833–841. doi:10.2147/NDT.S80881
   PubMed Web of Science ®Google Scholar
• Zhou FC, Lesch KP, Murphy DL. Serotonin uptake into dopamine neurons via dopamine transporters: a compensatory alternative. Brain Res. 2002;942:109–119. doi:10.1016/S0006-8993(02)02709-9
   Web of Science ®Google Scholar
• Valbrun LP, Zvonarev V. The opioid system and food intake: use of opiate antagonists in treatment of binge eating disorder and abnormal eating behavior. J Clin Med Res. 2020;12(2):41–63. doi:10.14740/jocmr4066
   Google Scholar
• National Center for Biotechnology Information PubChem compound summary for CID 3117, disulfiram; 2020 Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Disulfiram. Accessed January 12, 2021.
   Google Scholar
• Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35:217–238. doi:10.1038/npp.2009.110
   PubMed Web of Science ®Google Scholar
• Safer DL, Adler S, Dalai SS, et al. A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa. Int J Eat Disord. 2020;53(2):266–277. doi:10.1002/eat.23192
   PubMed Web of Science ®Google Scholar
• Appolinario JC, Nardi AE, McElroy SL. Investigational drugs for the treatment of binge eating disorder (BED): an update. Expert Opin Investig Drugs. 2019;28(12):1081–1094. doi:10.1080/13543784.2019.1692813
   PubMed Web of Science ®Google Scholar
• Citrome L, Goldman R, Tsai J, et al. Dasotraline for treatment of adults with binge-eating disorder: effect on binge-related obsessions and compulsions. CNS Spectr. 2020;25(2):307–308.
   Google Scholar
• Citrome L, Goldman R, Tsai J, et al. Effect of dasotraline on body weight in patients with binge-eating disorder. CNS Spectr. 2020;25(2):307.
   Google Scholar
• Tsai J, Navia B, McElroy SL, et al. 170 efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, double-blind, fixed-dose trial. CNS Spectr. 2020;25(2):308–309. doi:10.1017/S1092852920000863
   Google Scholar
• Goodman DW. Lisdexamfetamine dimesylate (vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorder. P & T. 2010;35(5):273–287.
   PubMedGoogle Scholar
• McElroy SL, Hudson JI, Mitchell JE, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72(3):235–246. doi:10.1001/jamapsychiatry.2014.2162
   PubMed Web of Science ®Google Scholar
• McElroy SL, Hudson J, Ferreira-Cornwell MC, et al. Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: results of two pivotal phase 3 randomized controlled trials. Neuropsychopharmacology. 2016;41(5):1251–1260. doi:10.1038/npp.2015.275
   PubMed Web of Science ®Google Scholar
• Hudson JI, McElroy SL, Ferreira-Cornwell MC, et al. Efficacy of lisdexamfetamine in adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2017;74(9):903–910. doi:10.1001/jamapsychiatry.2017.1889
   PubMed Web of Science ®Google Scholar
• Gasior M, Hudson J, Quintero J, et al. A phase 3, multicenter, open-label, 12-month extension safety and tolerability trial of lisdexamfetamine dimesylate in adults with binge eating disorder. J Clin Psychopharmacol. 2017;37(3):315–322. doi:10.1097/JCP.0000000000000702
   PubMed Web of Science ®Google Scholar
• Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present – a pharmacological and clinical perspective. J Psychopharmacol. 2013;27(6):479–496. doi:10.1177/0269881113482532
   PubMed Web of Science ®Google Scholar
• Quilty LC, Allen TA, Davis C, et al. A randomized comparison of long acting methylphenidate and cognitive behavioral therapy in the treatment of binge eating disorder. Psychiatry Res. 2019;273(273):467–474. doi:10.1016/j.psychres.2019.01.066
   Web of Science ®Google Scholar
• McElroy SL, Guerdjikova AI, Mori N, et al. Armodafinil in binge eating disorder: a randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2015;30(4):209–215. doi:10.1097/YIC.0000000000000079
   PubMed Web of Science ®Google Scholar
• Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity. 2009;17:30–39. doi:10.1038/oby.2008.461
   PubMed Web of Science ®Google Scholar
• White MA, Grilo CM. Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2013;74(4):400–406. doi:10.4088/JCP.12m08071
   PubMed Web of Science ®Google Scholar
• Guerdjikova AI, Walsh B, Shan K, et al. Concurrent improvement in both binge eating and depressive symptoms with naltrexone/bupropion therapy in overweight or obese subjects with major depressive disorder in an open-label, uncontrolled study. Adv Ther. 2017;34(10):2307–2315. doi:10.1007/s12325-017-0613-9
   PubMed Web of Science ®Google Scholar
• Carbone EA, Caroleo M, Rania M, et al. An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder. Eat Weight Disord. 2020. doi:10.1007/s40519-020-00910-x
   Web of Science ®Google Scholar
• Johnson PM, Kenny PJ. Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. Nat Neurosci. 2010;13(5):635–641. doi:10.1038/nn.2519
   PubMed Web of Science ®Google Scholar
• Latagliata EC, Patrono E, Puglisi-Allegrac S, Ventura R. Food seeking in spite of harmful consequences is under prefrontal cortical noradrenergic control. BMC Neurosci. 2010;11:15. doi:10.1186/1471-2202-11-15
   PubMed Web of Science ®Google Scholar
• Mahableshwarkar AR, Jacobsen PL, Serenko M, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. J Clin Psychiatry. 2015;76(5):583–591. doi:10.4088/JCP.14m09337
   PubMed Web of Science ®Google Scholar
• Robert SA, Rohana AG, Shah SA, et al. Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide - a pilot study. Obes Res Clin Pract. 2015;9(3):301–304. doi:10.1016/j.orcp.2015.03.005
   PubMed Web of Science ®Google Scholar
• Binge Eating Liraglutide Intervention (BELIEVE); 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT03279731?term=believe&draw=2&rank=3. Accessed January 12, 2021.
   Google Scholar
• Farci AM, Piras S, Murgia M, et al. Disulfiram for binge eating disorder: an open trail. Eat Behav. 2015;16:84–87. doi:10.1016/j.eatbeh.2014.10.008
   PubMed Web of Science ®Google Scholar
• Tata AL, Kockler DR. Topiramate for binge-eating disorder associated with obesity. Ann Pharmacother. 2006;40(11):1993–1997. doi:10.1345/aph.1H178
   Web of Science ®Google Scholar
• Guerdjikova AI, Williams S, Blom TJ, Mori N, McElroy SL. Combination phentermine-topiramate extended release for the treatment of binge eating disorder: an open-label, prospective study. Innov Clin Neurosci. 2018;15(5–6):17–21.
   PubMedGoogle Scholar
• Micioni Di Bonaventura MV, Lutz TA, Romano A, et al. Estrogenic suppression of binge-like eating elicited by cyclic food restriction and frustrative-nonreward stress in female rats. Int J Eat Disord. 2017;50(6):624–635. doi:10.1002/eat.22687
   PubMed Web of Science ®Google Scholar
• Cottone P, Wang X, Park JW, et al. Antagonism of sigma-1 receptors blocks compulsive-like eating. Neuropsychopharmacology. 2012;37(12):2593–2604. doi:10.1038/npp.2012.89
   Web of Science ®Google Scholar
• Piccoli L, Micioni Di Bonaventura MV, Cifani C, et al. Role of orexin-1 receptor mechanisms on compulsive food consumption in a model of binge eating in female rats. Neuropsychopharmacology. 2012;37(9):1999–2011. doi:10.1038/npp.2012.48
   PubMed Web of Science ®Google Scholar
• Kay K, Parise EM, Lilly N, et al. Hindbrain orexin 1 receptors influence palatable food intake, operant responding for food, and food-conditioned place preference in rats. Psychopharmacology (Berl). 2014;231(2):419–427. doi:10.1007/s00213-013-3248-9
   Web of Science ®Google Scholar
• Micioni Di Bonaventura MV, Cifani C, Lambertucci C, et al. A2A adenosine receptor agonists reduce both high-palatability and low-palatability food intake in female rats. Behav Pharmacol. 2012;23(5–6):567–574. doi:10.1097/FBP.0b013e3283566a60
   Web of Science ®Google Scholar